BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
– BRTX-100 is the first and only stem cell product candidate cleared…
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions
SUNNYVALE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. , a global…
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the…
Bay Area Cognitive Behavioral Therapy Center Expands Treatment Offerings with Acceptance and Commitment Therapy
SAN FRANCISCO, Feb. 22, 2025 (GLOBE NEWSWIRE) -- The Bay Area Cognitive…
Innovative Surface Treatment in the Electronics Industry
STEINHAGEN, Germany, Feb. 20, 2025 /PRNewswire/ -- Plasmatreat, a leading company in…
Rocket Doctor Signs Agreement with California Managed Care Plan
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR…
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI (mirdametinib), Manufactured By SpringWorks Therapeutics
LOUISVILLE, Ky., Feb. 17, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading…
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
MANAMA, Kingdom of Bahrain, Feb. 16, 2025 (GLOBE NEWSWIRE) -- The Bahrain…
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a…
FDA Approves Samsung Bioepis OSPOMYV, XBRYK (denosumab-dssb), a Biosimilar to Prolia and Xgeva
OSPOMYV™ and XBRYK™ approved by the U.S. Food and Drug Administration (FDA)…
